Search clinical trials for: sofosbubir/velpatasvir

Total 370 results

Gilead Sciences
Quintiles, Inc.

Completed

Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection (QUANTUM)

Hepatitis C, Chronic

United States, Puerto Rico
Alexandria University

Completed

Effect of Hepatitis C Clearance on Insulin Resistance

Hepatitis C | Insulin Resistance

Egypt
Sanjay Gandhi Postgraduate Institute of Medical...

Completed

Safety of Sofosbuvir in People With Advanced Kidney Failure

Hepatitis C | Kidney Failure, Chronic

India
Gilead Sciences

Completed

Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Chronic Hepatitis C Virus Infection in India

Hepatitis C Virus

India
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection

Hepatitis C Virus Infection

United States, New Zealand, Australia, United Kingdom
Saint Michael's Medical Center

Completed

Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study

HIV Infection | Hepatitis C Infection

United States
Valme University Hospital
Hospital General Universitario Elche; Hospital del SAS de Jerez; Clinica Universidad... and other collaborators

Completed

Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions (FPSMON201401)

Chronic Hepatitis C Infection

Spain
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis (VALOR-HCV)

Hepatitis C Virus Infection

United States
Humanity and Health Research Centre
Beijing 302 Hospital

Completed

SOF Plus DCV in Treating Chinese Treatment-experienced HCV Patients

Chronic Hepatitis C Infection

China
Gilead Sciences

Completed

Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Chronic Genotype 1 or 3 HCV Infection

Chronic HCV Infection

India
Gilead Sciences

Completed

Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation

Hepatitis C | Cirrhosis | Portal Hypertension | With or Without Liver Decompensation

United States, Spain, New Zealand, Australia, France
Humanity and Health Research Centre
Beijing 302 Hospital; Nanfang Hospital of Southern Medical University

Completed

DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO) (DASCO)

Chronic Hepatitis C Infection | Hepatitis B Reactivation | HBV Coinfection

China
Gilead Sciences

Completed

Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection

Hepatitis C Virus

Egypt
Tanta University

Unknown

Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients

Covid19

Egypt
Genuine Research Center, Egypt
Al-debeiky pharma

Completed

A Bio-equivalence Study of Sofosbuvir From Sofodelevier 400 mg Film Coated Tablets (Al-debeiky Pharma, Egypt) Versus Sovaldi 400 mg Tablets (Gilead Sciences, Canada)

Healthy

Egypt
Gilead Sciences

Completed

A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults

Chronic Hepatitis C | Human Immunodeficiency Virus

France, Italy, United Kingdom, Germany, Spain, Australia
National Liver Institute, Egypt

Completed

Eight Weeks Sofosbovir/Ledipasvir in HCV Infected Children Aged 4 to 10 Years

Hepatitis C, Chronic | Children, Only

Egypt
Beni-Suef University

Completed

Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients

Chronic Hepatitis C Virus Infection

Egypt
Almaza Military Fever Hospital

Completed

Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment

Covid19

Egypt
Genuine Research Center, Egypt
Magic Pharma, Egypt

Completed

A Bio-equivalence Study of Sofosbuvir From Magicbuvir 400 mg Film Coated Tablets ( Magic Pharma, Egypt) Versus Sovaldi 400 mg Tablets (Gilead Sciences, Canada)

Healthy

Egypt
Gilead Sciences

Completed

Sofosbuvir Plus Ribavirin in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection

Hepatitis C Virus

United States
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults

Hepatitis C | Human Immunodeficiency Virus

United States, Puerto Rico
Gilead Sciences

Completed

Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV Infection

Hepatitis C

Russian Federation
University of California, San Francisco
National Institutes of Health Clinical Center (CC); Johns Hopkins University; National Institute of Allergy and Infectious Diseases (NIAID) and other collaborators

Completed

Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant (STOP-CO)

Hepatitis C | HIV | Cirrhosis

United States
Kawin Technology Share-holding Co., Ltd.
KawinGreen Biotech Co., Ltd.

Completed

Safety and Efficacy of Generic Sofosbuvir and Ribavirin for Treatment-naive Genotype 2 Chronic Hepatitis C (SOF_GT2)

Hepatitis C, Chronic | Hepatitis C Virus Infection, Response to Therapy of

China
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis

Hepatitis C

France, Australia
Beni-Suef University

Completed

ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants

Chronic Hepatitis C Virus Infection

Egypt
Gilead Sciences

Completed

Use-Results Surveillance Study of Harvoni® in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection

Hepatitis C

Japan
Bristol-Myers Squibb

Withdrawn

A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 3

Hepatitis C

France, Canada
Tehran University of Medical Sciences

Completed

Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics (SD100)

Hepatitis C | Cirrhosis

Iran, Islamic Republic of
Janssen-Cilag International NV

Completed

An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus Infection

Hepatitis C

Egypt
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir Plus Ribavirin in Japanese Adults With Chronic Genotype 2 HCV Infection

Hepatitis C

Japan
ANRS, Emerging Infectious Diseases

Completed

Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir

Hepatitis C
Kaiser Permanente
City of Hope National Medical Center

Withdrawn

Ledipasvir/Sofosbuvir Treatment for Hepatitis C in HCT Recipients.

Hematopoietic Stem Cell Transplantation

United States
Gilead Sciences

Completed

Phase 3 Study of Sofosbuvir and Ribavirin (FISSION)

Hepatitis C

United States, Australia, Canada, Puerto Rico, New Zealand, Sweden, Italy, Netherlands
Postgraduate Institute of Medical Education and...
Directorate of Health and Family Welfare, Punjab

Unknown

Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab Model

Chronic Hepatitis c

India
National Institute of Allergy and Infectious Diseases...

Completed

Study of A Combination Pill With GS-7977 and GS-5885 for Hepatitis C in People With HIV

Hepatitis C | HIV

United States
Bristol-Myers Squibb

No longer available

EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C

Chronic Hepatitis C

Netherlands, Austria, Germany, United Kingdom, Sweden
Temple University

Unknown

Clinical Outcomes With Ceftolozane-tazobactam for MDR Pseudomonas Infections

Pseudomonas Infections | Pseudomonas Aeruginosa

United States
University of Southern California
National Cancer Institute (NCI)

Withdrawn

Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in Patients With Bladder Cancer

Bladder Carcinoma | Post-operative Pain

United States
University of Florida
Patient-Centered Outcomes Research Institute; Merck Sharp & Dohme LLC; AbbVie

Completed

Study of Oral Treatments for Hepatitis C (PRIORITIZE)

Chronic Hepatitis C

United States
Gilead Sciences

Completed

Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects

Chronic Hepatitis C Virus

United States
Janssen Infectious Diseases BVBA

Completed

Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis

Hepatitis C Virus Infection

United States, Canada
Genuine Research Center, Egypt
MinaPharm Pharmaceuticals

Completed

A Study of Sofosbuvir and Ledipasvir From Soviredia 90/400 mg Tablets (Minapharm, Egypt) Versus Harvoni 90/400 mg Tablets (Gilead Sciences, USA)

Healthy

Egypt
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir/Ledipasvir ± Ribavirin in Japanese Participants With Chronic Genotype 1 HCV Infection

Chronic HCV Infection

Japan
Gilead Sciences

Completed

SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection

Hepatitis C

United States, Canada, United Kingdom, Australia, New Zealand
Genuine Research Center, Egypt
Magic Pharma, Egypt

Completed

A Study of Sofosbuvir and Ledipasvir From Magicbuvir Plus 90/400 mg Tablets (Magic Pharma, Egypt) Versus Harvoni 90/400 mg Tablets (Gilead Sciences, USA)

Healthy

Egypt
Janssen Infectious Diseases BVBA

Completed

Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis

Hepatitis C Virus Infection

United States, Canada
National Hepatology & Tropical Medicine Research...
Cairo University

Unknown

Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC (FRI-STC)

Hepatocellular Carcinoma | Hepatitis C, Chronic

Egypt
Assiut University

Unknown

Effect Of DAAs For Treatment Of HCV On Normal Kidney

Antiviral Drug Adverse Reaction

3

Subscribe